Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debbie G J Robbrecht

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|July 4, 2012
[Mesenteric panniculitis: variable presentations]Debbie G J Robbrecht, Fazil Alidjan, Bob Eikemans, et al.
Journal of Pharmaceutical and Biomedical Analysis|January 11, 2024
Quantification and clinical validation of the selective MET kinase inhibitor DO-2 and its metabolites DO-5 and M3 in human plasmaBarend J Sikkema, Ron H J Mathijssen, Debbie G J Robbrecht, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 21, 2023
"If only I had", patients' experiences during early oncology trialsMaaike E A van Sasse van IJsselt, Diane A J van der Biessen, Andrea J van Puffelen, et al.
BJU International|September 3, 2025
Carbon footprint and staff demands of surgery and chemoradiation for muscle-invasive bladder cancerVera C Rutten, Simone A W Hesseling, Martine Franckena, et al.
British Journal of Cancer|October 6, 2020
A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumoursDebbie G J Robbrecht, Juanita Lopez, Emiliano Calvo, et al.
Cancer Reports (Hoboken, N.J.)|March 12, 2021
ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib studyMarit A C Vermunt, Debbie G J Robbrecht, Lot A Devriese, et al.
European Urology Open Science|January 12, 2024
Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide CohortAnke Richters, Debbie G J Robbrecht, Richard P Meijer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 17, 2025
First real-world clinical experience with [<sup>177</sup>Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteriaSui Wai Ling, Quido de Lussanet de la Sablonière, Michael Ananta, et al.
European Urology Oncology|April 29, 2025
Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort AnalysisDebbie G J Robbrecht, Youssra Salhi, John W M Martens, et al.
Cancer Immunology, Immunotherapy : CII|August 17, 2022
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancerMaud Rijnders, Debbie G J Robbrecht, Astrid A M Oostvogels, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Nederlands Tijdschrift Voor Geneeskunde|July 4, 2012
[Mesenteric panniculitis: variable presentations]Debbie G J Robbrecht, Fazil Alidjan, Bob Eikemans, et al.
Journal of Pharmaceutical and Biomedical Analysis|January 11, 2024
Quantification and clinical validation of the selective MET kinase inhibitor DO-2 and its metabolites DO-5 and M3 in human plasmaBarend J Sikkema, Ron H J Mathijssen, Debbie G J Robbrecht, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 21, 2023
"If only I had", patients' experiences during early oncology trialsMaaike E A van Sasse van IJsselt, Diane A J van der Biessen, Andrea J van Puffelen, et al.
BJU International|September 3, 2025
Carbon footprint and staff demands of surgery and chemoradiation for muscle-invasive bladder cancerVera C Rutten, Simone A W Hesseling, Martine Franckena, et al.
British Journal of Cancer|October 6, 2020
A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumoursDebbie G J Robbrecht, Juanita Lopez, Emiliano Calvo, et al.
Cancer Reports (Hoboken, N.J.)|March 12, 2021
ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib studyMarit A C Vermunt, Debbie G J Robbrecht, Lot A Devriese, et al.
European Urology Open Science|January 12, 2024
Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide CohortAnke Richters, Debbie G J Robbrecht, Richard P Meijer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 17, 2025
First real-world clinical experience with [<sup>177</sup>Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteriaSui Wai Ling, Quido de Lussanet de la Sablonière, Michael Ananta, et al.
European Urology Oncology|April 29, 2025
Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort AnalysisDebbie G J Robbrecht, Youssra Salhi, John W M Martens, et al.
Cancer Immunology, Immunotherapy : CII|August 17, 2022
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancerMaud Rijnders, Debbie G J Robbrecht, Astrid A M Oostvogels, et al.
Pageof 3